Norges Bank Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Norges Bank acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 125,551 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,540,000. Norges Bank owned about 0.23% of Supernus Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Supernus Pharmaceuticals by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock worth $222,411,000 after buying an additional 22,852 shares during the period. Geode Capital Management LLC increased its position in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after purchasing an additional 74,438 shares in the last quarter. American Century Companies Inc. raised its holdings in Supernus Pharmaceuticals by 9.2% in the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock valued at $41,248,000 after buying an additional 95,777 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Supernus Pharmaceuticals by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock valued at $27,242,000 after buying an additional 40,968 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Supernus Pharmaceuticals by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company’s stock valued at $14,449,000 after buying an additional 27,134 shares in the last quarter.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $31.76 on Thursday. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of 29.68 and a beta of 0.90. The firm’s fifty day moving average price is $33.82 and its 200 day moving average price is $35.02.

Analysts Set New Price Targets

SUPN has been the topic of a number of research reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at $307,444.95. This trade represents a 10.56 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is currently owned by insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.